Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

  • STATUS
    Recruiting
  • End date
    Dec 23, 2026
  • participants needed
    250
  • sponsor
    Hospices Civils de Lyon
Updated on 12 September 2021

Summary

This is a transnational prospective randomized trial comparing definitive carbon ion therapy versus photon or combined photon and protontherapy as standard treatment for unresectable or macroscopically uncompleted resected radioresistant tumors. Eligible tumors are axial chordoma (except of base of skull), adenoid cystic carcinoma of head and neck (except of trachea) and sarcomas of any site (except chondrosarcoma of the skull base), non previously irradiated and without pre-planned surgery or chemotherapy after the clinical trial procedure. Randomization is balanced 1 for 1. Patients of the experimental arm are treated in carbon ions centers in Europe and patients of the standard arm are treated in France in their closest participating radiotherapy center. An accrual of 250 patients is needed and an absolute difference of 20% of relapse free survival at five years is awaited. The main endpoint is the progression free survival at five years. The trial is supported by the French program of clinical research and the national health insurance. Two associated studies are carried out: a radiobiological one looking for radioresistance markers in the sarcomas biopsies, and the second one is about medico economics.

Details
Condition Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma, Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma, Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma, Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma, Malignant Tumors as Chordoma, Adenoid Cystic Carcinoma and Sarcoma
Treatment Carbon ions therapy, Advanced external radiotherapy by Xrays or protons
Clinical Study IdentifierNCT02838602
SponsorHospices Civils de Lyon
Last Modified on12 September 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

age 18 years
No severe comorbidity, life expectancy above 10 years
Unresectable or inoperable or R2 resection of the tumor
Eligible radioresistant tumor according to the limitative list as following
adenoid cystic carcinoma of head and neck (larynx and trachea excluded)
soft tissue sarcoma
pleomorphic rhabdomyosarcoma only (alveolar and embryonal forms excluded)
retroperitoneal sarcoma under condition of technical feasibility (movement)
osteosarcoma of any grade and localisation (Ewing excluded)
chondrosarcoma (except of skull base) OMS grade >= 2
chordoma axial skeleton or pelvis (except of skull base)
angiosarcoma
Absence of epidermal invasion (a hypodermic invasion is accepted with fixity of cutaneous plan but not true epidermal permeation)
Larger volume to be irradiated (PTV) less than 25 cm
ECOG Performance Status 2 or Karnovsky index 60
no pregnancy of possibility of pregnancy during the treatment
having an health insurance
signature of a written informed consent
validation of the randomization criteria: namely, a carbon ions therapy indication assessed by the medical team of a hadrontherapy center and able to by treated within two month from registration

Exclusion Criteria

Complete macroscopic or microscopic surgical resection (R0 or R1)
previous irradiation in the volume to be treated
any contra-indication to undergo a radiation therapy by Xray or particle therapy
metastatic disease
disease not candidate to a curative approach (example accelerated progressive diseaseresistant to nay medical treatment especially for sarcoma)
planned surgery or chemotherapy to take place after completion of radiotherapy (example : absence of enough space between an organ risk and the target volume (at least 5 mm) except the possibility of a spacer insertion)
planned surgery or chemotherapy after radiotherapy
Presence in the target volume of metallic material which cannot be removed (carbon fibres matreial authorized)
history of concomittant (except in situ cervix carcinoma; or any cured basocellular cutaneous cancer tor any cured cancer with no sign of relapse during 5 years))
impossible follow-up over 5 years
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note